Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
A pterygium (pl.: pterygia or pterygiums) is any wing-like triangular membrane occurring in the neck, eyes, knees, elbows, ankles or digits. The term comes from the Greek word pterygion meaning "wing".
==== Australia ==== Salvinorin A is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.
== History == Minocycline was a commonly used tetracycline synthesized in Lederle Laboratories in 1970, but antibiotic resistance to the drug began growing in prevalence throughout the 1970s and 1980s. While the problem of antibiotic resistance was known to scientists during the 1980s, apathy led to little federal attention given to the emerging crisis. However, by the late 1980s the worldwide threat began to be treated more seriously, which led to the renewed funding of antibiotic research. In 1993, researchers in the same laboratories that first synthesized minocycline created a new generation of tetracycline antibacterial agents, known as the glycylcyclines. These antibiotics were the first new drugs of the tetracycline class to be reported since the discovery of minocycline in 1970. The glycylcyclines were found to be active against a broad spectrum of tetracycline susceptible and resistant Gram (-) and Gram (+) aerobic and anaerobic bacteria. This initial research resulted in numerous studies being done on the antibacterial activity of various glycylcyclines, with extra focus being put on N,N-dimethylglycyl-amino derivatives, due to their reported potency. The aforementioned research culminated in a 1999 paper describing the discovery of a compound known as GAR-936, which would later be known as Tigecycline.
In 1946, Commodore Alfred Victor Knight of the Royal Australian Navy was awarded the commendation for honorary services. The citation described him as a 'forceful leader' who, by his 'splendid co-operation in the conduct of a vital training programme, aggressive determination and untiring energies ... contributed materially to combined large-scale operations'. On 3 September 1946, Vice Admiral Henry George Harry DeWolf of the Royal Canadian Navy was awarded the legion of Merit officer level for honorary services. The citation description "For exceptionally meritorious conduct in the performance of outstanding service while serving as Chief Staff Officer to Rear-Admiral G.C. Jones, RCN. He frequently conferred with Commander Task Force Twenty-four and his staff in connection with planning and the operational control of the surface forces under Commander Task Force Twenty-four. His excellent professional grasp of strategic and tactical situations, together with his intelligent and co-operative attitude, contributed materially to the success of operations conducted by Commander Task force Twenty-four." In 1947, Colonel Valentine Patrick Terrel Vivian head of counter-espionage, Section V, and Vice-Chief of the S.I.S. or MI6.
Sources: en.wikipedia.org
Following this incident, Biko's captors forced him to remain standing and shackled to the wall. The police later said that Biko had attacked one of them with a chair, forcing them to subdue him and place him in handcuffs and leg irons. Biko was examined by a doctor, Ivor Lang, who stated that there was no evidence of injury on Biko. Later scholarship has suggested Biko's injuries must have been obvious. He was then examined by two other doctors who, after a test showed blood cells to have entered Biko's spinal fluid, agreed that he should be transported to a prison hospital in Pretoria. On 11 September, police loaded him into the back of a Land Rover, naked and manacled, and drove him 740 miles (1,190 km) to the hospital. There, Biko died alone in a cell on 12 September 1977. According to an autopsy, an "extensive brain injury" had caused "centralisation of the blood circulation to such an extent that there had been intravasal blood coagulation, acute kidney failure, and uremia". He was the twenty-first person to die in a South African prison in twelve months, and the forty-sixth political detainee to die during interrogation since the government introduced laws permitting imprisonment without trial in 1963.
Positive action is designed to remedy historical disadvantage, but Australia has very few measures at federal level. Under the Disability Discrimination Act 1992 sections 4 to 6 require that an employer must make reasonable adjustments to accommodate people with disabilities at work. However, under section 11 the employer may escape this duty if they show that it would impose an unjustifiable hardship, taking account of the expenses and the employer’s capacity to afford it. For example, in Daghlian v Australian Postal Corporation it was held to be a reasonable adjustment that the employer provided a stool for a worker who would otherwise usually be required to stand. This modifies the “inherent requirements” defence found in section 21A(1)(b).
=== Ether lipids in bacteria === Though archaeol, featuring the ether linkage between isoprenoid chain to glycerol, has been considered as a biomarker for archaea, ether membrane lipids have also been discovered in some aerobic and anaerobic bacteria, including lipids with one ester bond and one ether bond to alkyl chains. Many strictly anoxic bacteria and a few aerobic species contain plasmalogens (Pla), which has an alkyl chain bound to sn-1 position of the glycerol via a vinyl-ether bond. Similar to archaea, these lipids are thought to increase the resistivity of bacteria to adverse environments. More stunning is the discovery of nonisoprenoid dialkyl glycerol diether lipids (DGD) and branched dialkyl glycerol tetraether lipids (brGDGT), which are formed, in the similar way to archaeol, by binding alkyls chains (but not isoprenoid chains) to glycerol molecules via ether linkage. It's highly notable that these lipids are only different from archaea ether lipids in the side chains and binding positions on the glycerol. DGD is reported in thermophilic bacteria, a few mesophilic bacteria and aggregating myxobacteria. In 2018, a group from the University of Groningen managed to produce a large amount (30% of total phospholipids) of true archaeol-based phospholipid in transgenic E. coli. They found that the modified cells show higher tolerance to heat and cold. The result builds on top of their earlier 2015 attempt, which produced only a minuscule amount.
coenzyme A (CoA) Also abbreviated SHCoA and CoASH. A coenzyme derived from pantothenic acid that functions as a substrate for a wide range of enzymes in all living organisms and is notable for its role as a carrier of acyl groups (e.g. acetyl) which attach to its terminal sulphydryl (SH) group via a thioester bond. Its acetylated form, known as acetyl-CoA, is particularly important to numerous metabolic pathways, both anabolic and catabolic, including the synthesis and oxidation of fatty acids and the oxidation of pyruvate as part of the citric acid cycle.
== Formulations == An oral suspension form is used for the prophylaxis or treatment of oropharyngeal thrush, a superficial candidal infection of the mouth and pharynx. A tablet form is preferred for candidal infections in the intestines. Nystatin is available as a topical cream and can be used for superficial candidal infections of the skin. Additionally, a liposomal formulation of nystatin was investigated in the 1980s and into the early 21st century. The liposomal form was intended to resolve problems arising from the poor solubility of the parent molecule and the associated systemic toxicity of the free drug. Nystatin pastilles have been shown to be more effective in treating oral candidiasis than nystatin suspensions. Due to its toxicity profile when high levels in the serum are obtained, no injectable formulations of nystatin are on the US market. However, injectable formulations have been investigated in the past.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.